Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)

Maria Teresa Voso, Emanuele Angelucci, Valeria Santini, Anna Angela Di Tucci, Giulia Quaresmini, Carlo Finelli, Antonio Volpe, Giovanni Quarta, Flavia Rivellini, Grazia Sanpaolo, Daniela Cilloni, Flavia Salvi, Giovanni Caocci, Alfredo Molteni, Daniele Vallisa, Susanna Fenu, Lorenza Borin, Giancarlo Latte, Giuliana Alimena, Alfonso PiciocchiPaola Fazi, Marco Vignetti, Sante Tura

Research output: Contribution to journalArticlepeer-review

68 Citations (Scopus)

Abstract

In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.
Original languageEnglish
Pages (from-to)N/A-N/A
JournalEuropean Journal of Haematology
DOIs
Publication statusPublished - 2014
Externally publishedYes

Keywords

  • Chelation Therapy
  • Deferasirox (DFX)
  • Iron Chelation
  • Iron Overload
  • Myelodysplastic Syndromes
  • Safety
  • Serum Ferritin

Fingerprint

Dive into the research topics of 'Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)'. Together they form a unique fingerprint.

Cite this